Claritev Corporation (CTEV) - Net Assets
Based on the latest financial reports, Claritev Corporation (CTEV) has net assets worth $-234.41 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.84 Billion) and total liabilities ($5.07 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check CTEV goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-234.41 Million |
| % of Total Assets | -4.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -107.13% |
| 10-Year Change | N/A |
| Growth Volatility | 110.31 |
Claritev Corporation - Net Assets Trend (2019–2025)
This chart illustrates how Claritev Corporation's net assets have evolved over time, based on quarterly financial data. See CTEV days of operational coverage to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Claritev Corporation (2019–2025)
The table below shows the annual net assets of Claritev Corporation from 2019 to 2025. For live valuation and market cap data, see CTEV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-167.18 Million | -298.97% |
| 2024-12-31 | $84.02 Million | -95.08% |
| 2023-12-31 | $1.71 Billion | -4.55% |
| 2022-12-31 | $1.79 Billion | -23.63% |
| 2021-12-31 | $2.34 Billion | -8.33% |
| 2020-12-31 | $2.56 Billion | +28.85% |
| 2019-12-31 | $1.99 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Claritev Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 481.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Comprehensive Income | $-4.17 Million | % |
| Other Components | $2.26 Billion | % |
| Total Equity | $-173.90 Million | 100.00% |
Claritev Corporation Competitors by Market Cap
The table below lists competitors of Claritev Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
$460.30 Million |
|
Mekonomen AB
ST:MEKO
|
$460.43 Million |
|
Traffic Control Technology Co Ltd
SHG:688015
|
$460.53 Million |
|
Fenerbahce Futbol AS
IS:FENER
|
$460.55 Million |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SHE:002365
|
$460.10 Million |
|
Thaitheparos Public Company Limited
BK:SAUCE
|
$460.06 Million |
|
Shivalik Bimetal Controls Limited
NSE:SBCL
|
$460.00 Million |
|
DINGDONG CAYMAN 2ADR/3 A
F:945
|
$459.79 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Claritev Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 84,022,000 to -173,900,000, a change of -257,922,000 (-307.0%).
- Net loss of 284,282,000 reduced equity.
- Other comprehensive income increased equity by 891,000.
- Other factors increased equity by 25,469,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-284.28 Million | -163.47% |
| Other Comprehensive Income | $891.00K | +0.51% |
| Other Changes | $25.47 Million | +14.65% |
| Total Change | $- | -306.97% |
Book Value vs Market Value Analysis
This analysis compares Claritev Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $72.19 | $29.42 | x |
| 2020-12-31 | $217.33 | $29.42 | x |
| 2021-12-31 | $143.95 | $29.42 | x |
| 2022-12-31 | $112.10 | $29.42 | x |
| 2023-12-31 | $105.97 | $29.42 | x |
| 2024-12-31 | $5.20 | $29.42 | x |
| 2025-12-31 | $-10.58 | $29.42 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Claritev Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -29.45%
- • Asset Turnover: 0.20x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-287.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.49% | 0.99% | 0.12x | 4.21x | $-188.81 Million |
| 2020 | -20.35% | -55.51% | 0.11x | 3.24x | $-776.35 Million |
| 2021 | 4.35% | 9.13% | 0.14x | 3.51x | $-132.39 Million |
| 2022 | -32.00% | -53.06% | 0.15x | 4.12x | $-751.97 Million |
| 2023 | -5.37% | -9.54% | 0.14x | 4.08x | $-262.61 Million |
| 2024 | -1958.81% | -176.85% | 0.18x | 61.30x | $-1.65 Billion |
| 2025 | 0.00% | -29.45% | 0.20x | 0.00x | $-266.89 Million |
Industry Comparison
This section compares Claritev Corporation's net assets metrics with peer companies in the Health Information Services industry.
Industry Context
- Industry: Health Information Services
- Average net assets among peers: $151,380,604
- Average return on equity (ROE) among peers: -38.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Claritev Corporation (CTEV) | $-234.41 Million | 0.49% | N/A | $460.29 Million |
| Aclarion Inc (ACON) | $2.23 Million | -317.55% | 0.31x | $1.82 Million |
| American Well Corp (AMWL) | $-204.41 Million | 0.00% | 0.00x | $126.97 Million |
| Heartbeam Inc (BEAT) | $310.49 Million | 13.79% | 0.89x | $40.74 Million |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG) | $-540.52K | 0.00% | 0.00x | $6.51 Million |
| BrightSpring Health Services, Inc. Common Stock (BTSG) | $784.08 Million | -6.88% | 5.94x | $10.63 Billion |
| Carlsmed, Inc. Common Stock (CARL) | $-70.63 Million | 0.00% | 0.00x | $273.75 Million |
| CareCloud, Inc. (CCLD) | $41.72 Million | -116.68% | 0.87x | $92.63 Million |
| Certara Inc (CERT) | $492.77 Million | -6.75% | 1.13x | $881.63 Million |
| CareMax Inc (CMAX) | $6.73 Million | 88.33% | 4.72x | $381.50 |
About Claritev Corporation
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary n… Read more